PMA device
GORE VIABAHN Endoprosthesis
W. L. Gore & Associates, Inc. · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Feb 8, 2007, newest May 26, 2022Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
PMA pathway
Device trials
30
Naming "GORE VIABAHN Endoprosthesis"
MAUDE reports
385
Brand "GORE VIABAHN Endoprosthesis", since 2015
PubMed studies
26
Mentioning "GORE VIABAHN Endoprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing GORE VIABAHN Endoprosthesis
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 15 decisions filed under this name.
- GORE VIABAHN EndoprosthesisPMA supplement
P040037-S152 · Decided May 26, 2022 · 101 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
5 more FDA decisions with a free account
Older decisions: P040037-S075, P040037-S060, P040037-S050, P040037-S030, P040037-S013, P040037-S007, P040037-S004, P040037-S003, P040037-S002
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "GORE VIABAHN Endoprosthesis", any status and sponsor, newest update first.
W.L.Gore & AssociatesNot on our public-company list
NCT06872905 · 158 participants (planned) · Start May 30, 2025 · Primary completion Aug 16, 2027
Device: GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX) · For: Aortoiliac Occlusive Disease
Sites: Birmingham, Alabama; Fresno, California; Tampa, Florida · 27 sites in all
29 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "GORE VIABAHN Endoprosthesis", and for the whole product code for context.
This brand
385 reports: 106 malfunction, 270 injury, 8 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- GORE VIABAHN ENDOPROSTHESIS WITH HEPARINMalfunction
23989659 · Received Jan 7, 2026 · Event dated Mar 31, 2025
Device type: Stent, Superficial Femoral Artery (NIP)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "GORE VIABAHN Endoprosthesis"[tiab]. The summary above synthesizes these.
- Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.
Soukas P, Becker M, Stark K, et al. · J Soc Cardiovasc Angiogr Interv · 2023
- Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.
Iida O, Ohki T, Soga Y, et al. · Vasc Med · 2024Multicenter Study, Observational Study
- Erratum: Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.
Soukas P, Becker M, Stark K, et al. · J Soc Cardiovasc Angiogr Interv · 2023Published Erratum
- A Very Rare Cause of Thrombotic Peripheral Occlusion.
Kretzschmar D, Thieme M, Aschenbach R, et al. · Int J Angiol · 2023Case Reports
- Adherence to instruction for use after endovascular repair of popliteal artery aneurysm.
Wrede A, Lehti L, Eiberg JP, et al. · Vascular · 2022
- Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design.
Noory E, Böhme T, Salm J, et al. · J Clin Med · 2023
- Laser Atherectomy and Restenting of the Superficial Femoral Artery Using GORE VIABAHN Endoprosthesis Following Failure of Both Bare-Metal Stenting and Surgical Revascularization.
Khawer A, Diaz CF · Case Rep Vasc Med · 2024Case Reports
- One-Year Clinical Outcomes of a Self-Expanding Covered Stent for Aortoiliac Occlusive Disease.
Reijnen MMPJ, Mezes P, Tigkiropoulos K · J Endovasc Ther · 2025
- Treatment with a self-expanding endoprosthesis in patients with stenosis or occlusion at the arteriovenous graft: 6-Month outcomes of a post-marketing surveillance study.
Haruguchi H, Fukasawa M, Ikeda K, et al. · J Vasc Access · 2025Multicenter Study
- Interventional repair of a vascular aneurysm in a patient with Marfan syndrome.
Ghonem ME, Yuan X, Mitsis A, et al. · SAGE Open Med Case Rep · 2018Case Reports
- Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial.
Bosiers M, Deloose K, Callaert J, et al. · J Cardiovasc Surg (Torino) · 2020Multicenter Study, Randomized Controlled Trial
- Endovascular Management of Right Subclavian Artery Pseudoaneurysm due to War Injury in Adolescent Patient.
Saydam O, Şerefli D, Atay M, et al. · Case Rep Vasc Med · 2017Case Reports
Other devices of this type
Also filed under product code NIP.
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.